191 related articles for article (PubMed ID: 22850548)
1. Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation.
Starlinger P; Alidzanovic L; Schauer D; Maier T; Nemeth C; Perisanidis B; Tamandl D; Gruenberger B; Gruenberger T; Brostjan C
Br J Cancer; 2012 Sep; 107(6):961-6. PubMed ID: 22850548
[TBL] [Abstract][Full Text] [Related]
2. Perioperative complications after neoadjuvant chemotherapy with and without bevacizumab for colorectal liver metastases.
Lubezky N; Winograd E; Papoulas M; Lahat G; Shacham-Shmueli E; Geva R; Nakache R; Klausner J; Ben-Haim M
J Gastrointest Surg; 2013 Mar; 17(3):527-32. PubMed ID: 23299220
[TBL] [Abstract][Full Text] [Related]
3. Preoperative administration of bevacizumab is safe for patients with colorectal liver metastases.
Li DB; Ye F; Wu XR; Wu LP; Chen JX; Li B; Zhou YM
World J Gastroenterol; 2013 Feb; 19(5):761-8. PubMed ID: 23431050
[TBL] [Abstract][Full Text] [Related]
4. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study.
D'Angelica M; Kornprat P; Gonen M; Chung KY; Jarnagin WR; DeMatteo RP; Fong Y; Kemeny N; Blumgart LH; Saltz LB
Ann Surg Oncol; 2007 Feb; 14(2):759-65. PubMed ID: 17103075
[TBL] [Abstract][Full Text] [Related]
5. Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study.
Mahfud M; Breitenstein S; El-Badry AM; Puhan M; Rickenbacher A; Samaras P; Pessaux P; Lopez-Ben S; Jaeck D; Figueras J; Alain-Clavien P
World J Surg; 2010 Jan; 34(1):92-100. PubMed ID: 19838754
[TBL] [Abstract][Full Text] [Related]
6. Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases.
van der Pool AE; Marsman HA; Verheij J; Ten Kate FJ; Eggermont AM; Ijzermans JN; Verhoef C
J Surg Oncol; 2012 Dec; 106(7):892-7. PubMed ID: 22552819
[TBL] [Abstract][Full Text] [Related]
7. Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience.
Wolf PS; Park JO; Bao F; Allen PJ; DeMatteo RP; Fong Y; Jarnagin WR; Kingham TP; Gönen M; Kemeny N; Shia J; D'Angelica MI
J Am Coll Surg; 2013 Jan; 216(1):41-9. PubMed ID: 23041049
[TBL] [Abstract][Full Text] [Related]
8. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557
[TBL] [Abstract][Full Text] [Related]
9. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases.
Kesmodel SB; Ellis LM; Lin E; Chang GJ; Abdalla EK; Kopetz S; Vauthey JN; Rodriguez-Bigas MA; Curley SA; Feig BW
J Clin Oncol; 2008 Nov; 26(32):5254-60. PubMed ID: 18854565
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels.
Brostjan C; Gebhardt K; Gruenberger B; Steinrueck V; Zommer H; Freudenthaler H; Roka S; Gruenberger T
Clin Cancer Res; 2008 Apr; 14(7):2065-74. PubMed ID: 18381946
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.
Gruenberger B; Tamandl D; Schueller J; Scheithauer W; Zielinski C; Herbst F; Gruenberger T
J Clin Oncol; 2008 Apr; 26(11):1830-5. PubMed ID: 18398148
[TBL] [Abstract][Full Text] [Related]
12. Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study.
Tamandl D; Gruenberger B; Klinger M; Herberger B; Kaczirek K; Fleischmann E; Gruenberger T
Ann Surg; 2010 Jul; 252(1):124-30. PubMed ID: 20562613
[TBL] [Abstract][Full Text] [Related]
13. [Preoperative chemotherapy in the surgical treatment of colorectal liver metastases].
Dede K; Láng I; Pörneczi B; Mester G; Fekete A; Kőszegi G; Mersich T; Besznyák I; Bursics A
Magy Seb; 2013 Dec; 66(6):325-30. PubMed ID: 24333977
[TBL] [Abstract][Full Text] [Related]
14. Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis.
Chaudhury P; Hassanain M; Bouganim N; Salman A; Kavan P; Metrakos P
HPB (Oxford); 2010 Feb; 12(1):37-42. PubMed ID: 20495643
[TBL] [Abstract][Full Text] [Related]
15. [HEMIHEPATECTOMY FOR RESECTABLE HEPATIC METASTASIS FROM COLORECTAL CANCER WITH POOR PROGNOSIS].
Patyutko YI; Kotelnikov AG; Mamontov KG; Podluzhny DV; Ponomarenko AA
Vopr Onkol; 2015; 61(3):439-47. PubMed ID: 26242159
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
[TBL] [Abstract][Full Text] [Related]
17. Impact of preoperative targeted therapy on postoperative complications after resection of colorectal liver metastases.
Neeff HP; Drognitz O; Klock A; Illerhaus G; Opitz OG; Hopt UT; Makowiec F
Int J Colorectal Dis; 2012 May; 27(5):635-45. PubMed ID: 22139030
[TBL] [Abstract][Full Text] [Related]
18. A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases.
Chun YJ; Kim SG; Lee KW; Cho SH; Kim TW; Baek JY; Park YS; Hong S; Chu CW; Beom SH; Jung M; Shin SJ; Ahn JB
Clin Colorectal Cancer; 2020 Sep; 19(3):e140-e150. PubMed ID: 32402681
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin.
Eveno C; Passot G; Goéré D; Soyer P; Gayat E; Glehen O; Elias D; Pocard M
Ann Surg Oncol; 2014 Jun; 21(6):1792-800. PubMed ID: 24337648
[TBL] [Abstract][Full Text] [Related]
20. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.
Wong R; Cunningham D; Barbachano Y; Saffery C; Valle J; Hickish T; Mudan S; Brown G; Khan A; Wotherspoon A; Strimpakos AS; Thomas J; Compton S; Chua YJ; Chau I
Ann Oncol; 2011 Sep; 22(9):2042-2048. PubMed ID: 21285134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
